Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Nikolas Von Bubnoff*, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser

*Corresponding author for this work
17 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)'. Together they form a unique fingerprint.

Medicine & Life Sciences